New Injectable Agents for the Treatment of Type 2 Diabetes Part 2—Glucagon-Like Peptide-1 (GLP-1) Agonists - 29/10/18
Doi : 10.1016/j.amjmed.2018.05.043
Christa George, PharmD, BCPS, CDE, BCACP a, b, ⁎ 
, AhYoung Byun, PharmD b, Amanda Howard-Thompson, PharmD, BCPS, CDE a, b
, AhYoung Byun, PharmD b, Amanda Howard-Thompson, PharmD, BCPS, CDE a, b a Department of Clinical Pharmacy
b Department of Family Medicine, University of Tennessee Health Science Center, Memphis
⁎Requests for reprints should be addressed to Christa M. George, PharmD, BCPS, CDE, BCACP, Department of Clinical Pharmacy, University of Tennessee Health Science Center, 881 Madison Avenue, Room 215, Memphis, TN 38163Department of Clinical PharmacyUniversity of Tennessee Health Science Center,881 Madison Avenue, Rm Room 215MemphisTN38163
Pharmacology Series Editor, Rhonda M. Cooper-DeHoff, PharmD, MS
Abstract |
The US Food and Drug Administration has recently approved several new glucagon-like peptide-1 (GLP-1) agonists alone and in combination with various insulin products. The second of 2 articles in a series, this review will describe the potential advantages and disadvantages of the GLP-1 agonist class of products.
Le texte complet de cet article est disponible en PDF.Keywords : GLP-1 combination products, Glucagon like peptide-1 (GLP-1) agonist, Type 2 diabetes
Plan
| Funding: None. |
|
| Conflict of Interest: None. |
|
| Authorship: All authors had access to data and a role in writing this manuscript. |
© 2018
Publié par Elsevier Masson SAS.
Vol 131 - N° 11
P. 1304-1306 - novembre 2018 Retour au numéro
Article précédent
- Paget's Disease of Bone: Diagnosis and Treatment
- Igor Kravets
- Menace Elbow: Disseminated Nocardiosis
- Rupak Datta, Erik Kramer, Harald Reinhart, Sheldon Campbell, Ellice Wong, Shaili Gupta
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?